28 Jul 2023 --- The US FDA is receiving criticism for its lack of regulatory action on cannabidiol (CBD), this week organizations have sent testimonies questioning how there can be a lack of CBD laws when dietary supplements became part of the FDA’s regulation three decades ago. “The FDA will claim that they need more time. However, this assertion is deliberate and not without severe public health consequences and further confusion in the marketplace,” says Dr. Daniel Fabricant, president and CEO at the National Product Association (NPA).
